TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01266733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment
Description: The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment of fibromyalgia
Description: The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
Study: NCT01116986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive phone counseling during the quit attempt
Description: Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
Study: NCT02673424

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided stenting
Description: The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided stenting
Description: The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)
Study: NCT04481477

Intervention type: OTHER
Intervention: Nursing care to reduce anxiety, fear and loneliness
Description: Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
Study: NCT01749605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 250 mg BID x 3 days
Study: NCT00421200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (HES 130/0.4)
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
Study: NCT04107350

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: whole-body vibration
Description: 10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: 10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
Study: NCT01707225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
Study: NCT00247377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass surgery
Description: in order to meet health requirements for patient, gastric bypass surgery was undergone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap-Band
Description: in order to meet health requirements for patient, gastric band surgery was undergone
Study: NCT02573220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study: NCT05430893

Intervention type: OTHER
Intervention: Botulinum Toxin A
Description: 100 UI IM in the adductor longus
Study: NCT00992433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza H1N1 vaccine
Description: Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza H1N1 vaccine
Description: Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
Study: NCT03800641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: oral, intravenous and nasal administration of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: oral, intravenous and nasal administration of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: oral, intravenous and nasal administration of Dexmedetomidine
Study: NCT01313637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25mcg
Description: 125/25mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125mcg
Description: 125mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25mcg
Description: 25mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo only
Description: Placebo
Study: NCT03177278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-plazomicin
Description: single intravenous dose
Study: NCT03126708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab (EGFR monoclonal antibody) plus standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin plus paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus paclitaxel
Description: Chemotherapy
Study: NCT00221169

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection
Description: pet ct prior to surgery
Study: NCT03354806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous peripheral nerve blocks
Description: 6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic treatment
Description: 6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
Study: NCT01589666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 100 mL Spray-dried S/D-treated Plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated plasma
Description: Infusion of 200mL Spray-dried S/D-treated plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 500 mL Spray-dried S/D-treated plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 750 mL Spray-dried S/D-treated Plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 800 mL Spray-dried S/D-treated Plasma
Study: NCT02229045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Bound Paclitaxel
Description: Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
Study: NCT04152460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscalor Bulk (VOCO,Cuxhaven)
Description: Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grandioso x-tra
Description: Nanohybrid Bulk Resin Composite
Study: NCT03575754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ultrasound Gastrostomy
Description: A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
Study: NCT00502021

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manioc powder (placebo) 60 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid/ALA
Description: Flaxseed powder 60 g/day (10 g ALA)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha linolenic acid/ALA
Description: Flaxseed oil 30 ml/day (10 g ALA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil 30 ml/day
Study: NCT00744523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mo.Ma cerebral protection device
Description: Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
Study: NCT02904486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: change behavior
Description: Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: change behavior
Description: Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
Study: NCT00484731

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration with Saline
Description: Infiltration with Bupivacaine according to protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with Bupivacaine
Study: NCT04528927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg (1st day) then 250 mg / D for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg (1st day) then 250 mg / D for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg (1st day) then 250 mg / D for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg per day for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 220 mg per day for 10 days
Study: NCT04312321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandatory phone call consultation
Description: Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandatory audiovisual consultation
Description: Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
Study: NCT03054480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Micro-Needle Radiofrequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Study: NCT00629330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
Study: NCT02149082

Intervention type: DEVICE
Intervention: Infrascanner Model 2000
Description: The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
Study: NCT02261597

Intervention type: BEHAVIORAL
Intervention: Cold Pressor Test
Description: Repeated immersion of hand in ice-cold water

Intervention type: BEHAVIORAL
Intervention: Cold Pressor Test
Description: Repeated immersion of hand in ice-cold water
Study: NCT03422354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided PVB with General Aneasthesia
Description: An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Patients will receive single shot L1-L2 PVB before undergoing GA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Aneasthesia
Description: General Aneasthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Aneasthesia
Description: General Aneasthesia
Study: NCT03558360

Intervention type: DIAGNOSTIC_TEST
Intervention: Impedance measurement
Description: Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
Study: NCT01383772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pan retinal Photocoagulation
Description: All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
Study: NCT04354844

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: questionnaire
Study: NCT03588728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation targeting the right inferior frontal gyrus

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation targeting the right inferior frontal gyrus

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation (CR)
Description: Cognitive exercises on a computer designed to increase attention, memory, and processing speed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
Study: NCT01222273

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: cholecalciferol (Vitamin D3)
Description: 4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
Study: NCT01130584

Intervention type: OTHER
Intervention: Pyruvate kinase isoform M2
Study: NCT01932554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Description: intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous hydration
Description: intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral narcotic
Description: Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parenteral narcotic
Description: Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Description: Patients will perform incentive spirometry every 2 hours while awake
Study: NCT01116986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive phone counseling during the quit attempt
Description: Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive phone counseling during the quit attempt
Description: Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
Study: NCT01932554

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Incentive spirometry
Description: Patients will perform incentive spirometry every 2 hours while awake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental oxygen
Description: Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.